aff
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial2018· article· en· The Lancet· Medicine
204
citations
Every work in the frame. Each row carries the routes that admitted it, because a frame that forgets how it found something cannot be audited.